Metrics as of 10/14/2026, 11:23 PM (Berlin time), refresh in progress.
Akari Therapeutics Stock
Akari Therapeutics, Plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Abizer Gaslightwala
- Employees
- 6
- Market cap
- $17 M
- IPO
- 06/01/2014
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a…
Akari Therapeutics stock: price history
1D
-7.5%
1W
-6.7%
1M
-19.2%
6M
+41.0%
YTD
-29.2%
1Y
-73.4%
2Y
-91.9%
5Y
-99.4%
10Y
-99.9%
Next earnings date
Next earnings date
04/12/2026 (in 48 days)
Volatility around earnings
~73% stronger price swings than usual
Ask the agents about Akari Therapeutics
Analyst assessment of Akari Therapeutics
PRICE TARGET LOW
US$19.50
CONSENSUS
US$24.75
MEDIAN
US$24.75
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 20/07/2026
Akari Therapeutics stock metrics
P/E
-0
P/B
0.7
EV/EBITDA
-0.31
RETURN ON EQUITY
-25.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
47.5%
FLOAT SHARES
1,090,776
AVG. DAILY VOLUME (30D)
63,792
Insider transactions (SEC)
Prudo-Chlebosz Raymond
Gaslightwala Abizer
Gaslightwala Abizer
Bazemore Robert B
Bazemore Robert B
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Akari Therapeutics stock
What does Akari Therapeutics do?
Akari Therapeutics, Plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Abizer Gaslightwala, the company employs around 6 people.
The IPO was on 06/01/2014; the stock trades on NASDAQ under the ticker AKTX.
What do analysts say about Akari Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 20/07/2026).
The average price target is US$24.75, ranging from US$19.50 to US$30.00, with a median of US$24.75.
This is an external assessment, not a statement by Market Jury.
When does Akari Therapeutics report next?
The next earnings date is 04/12/2026.
Around past earnings, price swings were roughly 73% stronger than usual.
Does Akari Therapeutics pay a dividend?
No, Akari Therapeutics currently does not pay a dividend.
Which stocks are comparable to Akari Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Akari Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Akari Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.